key: cord-1015373-dm9nefdg
authors: Lang, Joshua P.; Wang, Xiaowen; Moura, Filipe A.; Siddiqi, Hasan K.; Morrow, David A.; Bohula, Erin A.
title: A current review of COVID-19 for the cardiovascular specialist
date: 2020-05-03
journal: Am Heart J
DOI: 10.1016/j.ahj.2020.04.025
sha: 9da2ea921dcea8312b8c1491c1dd004bd42a53a8
doc_id: 1015373
cord_uid: dm9nefdg

Abstract Although Coronavirus Disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes. However, whether pre-existing cardiovascular disease is an independent determinant of higher mortality risk with COVID-19 remains uncertain. Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, occurs in up to ~60% of hospitalized patients with severe COVID-19. Potential contributors to acute cardiac injury in the setting of COVID-19 include 1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; 2) acute coronary syndrome due to acute atherothrombosis in a virally-induced thrombotic and inflammatory milieu; 3) microvascular dysfunction due to diffuse microthrombi or vascular injury; 4) stress-related cardiomyopathy (Takotsubo syndrome); 5) non-ischemic myocardial injury due to a hyperinflammatory cytokine storm; or 6) direct viral cardiomyocyte toxicity and myocarditis. Diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID-19. Practitioners should be vigilant for cardiovascular complications of COVID-19. Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, d-dimer, and inflammatory biomarkers. Management decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative non-ischemic causes of injury, integrating the level of suspicion for COVID-19.

J o u r n a l P r e -p r o o f Page 4 of 34 SARS-CoV-2 appears to also be transmitted by asymptomatic individuals. At least one study from Asia with extensive contact tracing identified 7 clusters of cases for which spread of the virus occurred 1-3 days prior to symptom development in the source patient. In addition, it has been estimated that prior to travel restrictions in China, 86% of infections were undocumented-meaning undiagnosed and not reported. 14 A study comparing the stability of SARS-CoV-2 and SARS-CoV found these virions to be stable in aerosols for hours (half-life ~1 hour) and on plastic and metal surfaces for up to 72 hours (half-life ~7 hours). 15 Moreover, the National Institute of Infectious Disease in Japan reported detection of SARS-CoV-2 RNA on surfaces in the cabins of a cruise ship with infected passengers up to 17 days after they were vacated. 16 Studies from the early stages of the epidemic in China, prior to implementation of full mitigation strategies, estimated a basic reproductive number (R o ) of 2.38 for SARS-CoV-2, meaning that every infected individual will, on average, spread the virus to 2 to 3 other individuals.

It has been proposed that COVID-19 progresses through several stages in its disease course. 8, 17 The first stage is viral infection during which constitutional symptoms, such as fever and cough, predominate. The second stage is characterized by direct viral cytoxic effects, particular those in the respiratory tract, leading to respiratory failure and potentially ARDS. The third and final stage, which is of particular concern to cardiologists, is thought to be mediated by a hyper-inflammatory response to the virus causing systemic effects, including those on the cardiovascular system. diabetes mellitus, and known coronary artery disease were associated with adverse outcomes in COVID- 19 . In a survey by the China CDC, among patients diagnosed with COVID-19, 13% had hypertension, 5% had diabetes mellitus, and 4% had a history of cardiovascular disease. 18 In this same study, among patients who died, 40% had hypertension, 20% had diabetes and 22% had pre-existing cardiovascular disease. Of these and a broad group of other comorbidities, cardiovascular disease was associated with the highest case fatality rate (10.5%). Several smaller, peer-reviewed case series ranging in size from ~100-1000 hospitalized patients have reported similar results, with higher rates of older age, hypertension, diabetes and cardiovascular disease in patients with more severe manifestations of COVID-19. 3, 4, 19, 20 However, whether pre-existing cardiovascular disease is independently associated with higher mortality risk with COVID-19 remains uncertain. In a study of 191 patients, only older age, elevated d-dimer and a higher admission Sequential Organ Failure Assessment (SOFA) score were independently associated with mortality. 4 Thus, the observed unadjusted associations between hypertension, diabetes and coronary artery disease with worse outcomes in COVID-19 may, in fact, predominantly be a reflection of the higher prevalence of these diseases with increasing age.

In addition to these epidemiological observations, an understanding of CoV biology, including SARS-CoV-2 entry into cells via transmembrane ACE2, has also raised the possibility of an increased risk for patients with certain underlying cardiovascular conditions. In animal models,ACE2 is upregulated with hypertension and with ACE inhibition, 21 theoretically creating an increased susceptibility to CoV infection. Furthermore, while genetic inactivation of ACE2 causes severe lung injury in avian influenza-challenged mice, the restitution of ACE2 levels seem to mitigate lung injury in this preclinical model of viral infection. 22 These considerations, 10 were amplified by social media and led to concern in the medical community about the use of ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), or angiotensin receptor-neprilysin inhibitors J o u r n a l P r e -p r o o f 

Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, appears to be prevalent in subgroups of hospitalized patients with COVID-19. [2] [3] [4] 26 However, both the epidemiology across the clinical spectrum of patients with COVID-19 and the mechanisms of acute injury remain uncertain.

In one of the first reports to include measurement of cardiac troponin, Zhou reference range for individuals who survived. 26 These investigators speculated that acute coronary syndrome (ACS) in the setting of an acute inflammatory state was a cause of injury and cited a pathologist's examination of a patient who died of COVID-19 and had evidence of acute myocardial infarction.

Two single-center studies from academic hospitals in Wuhan, China also described this clinical finding. 2 26 In-hospital mortality was more than 6-fold higher in patients with elevated cTnT levels than in patients with normal cTnT levels (59.6% vs 8.9%). Moreover, patients with underlying cardiovascular disease and increased cTnT levels comprised a subgroup with even higher mortality (69.44%). In contrast, patients with underlying cardiovascular disease without cTnT elevation experienced a more favorable prognosis (mortality 13.33%), albeit still higher than patients without CVD or elevated cTnT (mortality 7.62%). In this study, cTnT levels were statistically significantly correlated with the blood concentrations of C-reactive protein (r 2 =0.281) and N-terminal pro-B-type natriuretic peptide (NT-proBNP, r 2 =0.376); suggesting a link to the degree of systemic inflammation and myocardial wall stress. In both studies, patients with evidence of myocardial injury were also older with a higher prevalence of coronary heart disease, cerebrovascular disease, chronic heart failure, chronic renal failure, chronic obstructive pulmonary disease, hypertension, and diabetes. 2 left ventricular ejection fraction, 5 (62%) had regional wall-motion abnormalities on echocardiography, and 6 (33%) were found to have obstructive coronary disease on coronary angiography. In this series, 72% of patients presenting with ST elevation on ECG died in hospital.

In aggregate, these data suggest that acute myocardial injury may be an important marker of disease severity and adverse prognosis in COVID-19.

However, the mechanism(s) underlying this association remain unclear and plausibly multiple in etiology (Figure 2) . Potential contributors to acute cardiac injury in the setting of COVID-19 include 1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; 2) acute coronary syndrome due to acute atherothrombosis in a virally-induced thrombotic and inflammatory milieu; 3) microvascular dysfunction due to diffuse microthrombi or vascular injury; 4) stress-related cardiomyopathy (Takotsubo syndrome); 5) non-ischemic myocardial injury due to a hyperinflammatory cytokine storm; or 6) direct viral cardiomyocyte toxicity and myocarditis. 8 In the setting of critical illness, these possible contributors can be very difficult to distinguish on clinical grounds. Moreover, treatment is likely to vary substantially depending on whether the suspected etiology is coronary plaque rupture or a combination of oxygen supply-demand mismatch and myocytotoxic effect of pathogens, endotoxins, cytokines, or reactive oxygen radicals induced by infectious processes. 28 In terms of management of these patients, the decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative non-ischemic causes of injury, integrating the level of suspicion for COVID-19. For example, according to a recent statement by the Society for Cardiovascular Angiography and Interventions (SCAI), patients presenting with presumed ST-elevation myocardial infarction (STEMI) should be treated with primary percutaneous coronary intervention (PCI) unless there is a heightened concern for the prevalence of COVID-19 causing systematic and infrastructural J o u r n a l P r e -p r o o f Page 9 of 34 delays in care. 29 In the latter situation, it may reasonable to consider fibrinolytic therapy in a low risk hemodynamically stable patient with STEMI if there is a limitation in availability for PCI due to stressed resources. However, at the present time, primary PCI should be utilized for the majority of STEMIs. In the case of suspected non-ST elevation myocardial infarction (NSTEMI), efforts should be taken to try to differentiate between an occlusive event or a demand process with tools such as electrocardiogram, echocardiogram, and coronary CT angiography. The SCAI statement also proposed that it is reasonable to consider deferring invasive management; especially if the patient is hemodynamically stable. Coronary angiography, when performed, may also reveal the absence of critical epicardial disease, leading to alternative diagnoses, including Takotsubo syndrome or acute myocarditis. 30 There is intense scientific and clinical interest in determining the underlying etiology of acute myocardial injury in COVID-19. Epidemiologic and clinical studies of influenza have demonstrated that patients with underlying coronary artery disease and risk factors for atherosclerosis have an increased risk of developing an ACS during acute infections. 31, 32 In addition, case reports have described viral myocarditis among COVID-19 patients, though none confirmed by biopsy. 33, 34 Furthermore, patients with general critical illness commonly have elevated troponin levels in the absence of obvious ischemia, and are at increased risk of death. 35 The complex relationship between direct deleterious cardiovascular effects specific to SARS -CoV-2 and the cascade effects of the host immune response needs to be further elucidated. Mechanisms for myocardial injury and dysfunction in the setting of severe inflammation and cytokine storm are not currently well defined, and include direct myocyte depression as a result of the inflammatory milieu as has been reported in sepsisinduced cardiomyopathy. Animal studies show that elevated cytokines and inflammatory mediators like TNF-α and IL-6 lead to decreased contractility, possibly mediated through calcium dependent pathways. [36] [37] [38] 

Myocarditis and pericarditis are potential cardiovascular manifestations of COVID-19; although available evidence is mixed and largely based on singlepatient case reports. 33, 34, 39 A case report from Hu et al reports the evaluation of a 37 year old male in China who presented with chest pain, dyspnea and diarrhea and was found to have fulminant myocarditis with acute elevations in cTnT (>10,000ng/L) and NT-proBNP (>20,000 ng/L) and LVEF 27%, with clean coronaries on CT coronary angiography. He was treated with IVIG and methylprednisolone for immunosuppression, along with supportive care with vasopressors and diuretics, and ultimately had recovery of LV function (LVEF 66%) and improved biomarkers. 33 A subsequent case report from Northern Italy described a 53-year-old woman with confirmed SARS-CoV-2 infection, who presented with fatigue, elevated cardiac biomarkers, ECG changes, and a depressed LVEF to 40% with diffuse hypokinesis. A cardiac MRI showed increased wall thickness, diffuse biventricular hypokinesis, and diffuse late gadolinium enhancement involving most of the myocardium. Notably, her Creactive protein was never elevated above the reference range and she never suffered from respiratory failure. She was treated with antivirals, including lopinavir/ritonavir, and intravenous methylprednisolone (1mg/kg daily for three days) and on day 6 a repeat echocardiogram showed partial recovery of her LVEF. This report suggests diffuse myocardial inflammation in some cases rather than secondary inflammatory myocardial suppression. Other coronaviruses, including MERS-CoV, have been reported to cause acute myocarditis and heart failure. 40 It remains possible that in some cases SARS-CoV-2 causes myocardial dysfunction through viral myocarditis; however, at the point of this writing, pathological evaluation of suspected cases of COVID-19-associated myocarditis, including the possibility of viral entry into cardiomyocytes is extremely limited. In a case report of a 69 year old woman presenting with COVID-19 and cardiogenic shock, endomyocardial biopsy revealed coronavirus particles within cytopathic interstitial cells of the myocardium but not in myocytes or endothelial cells. 41 In a 43 year-old woman with COVID-19 and ST-elevation with mild left ventricular dysfunction, endomyocardial biopsy demonstrated diffuse T-lymphocytic inflammatory infiltrates with interstitial edema and limited foci of necrosis without SARS-CoV-2 within the myocardium rendering a final diagnosis of a virusnegative lymphocytic myocarditis. 42 The coronary microvasculature and endothelium may be at risk for viral entry, due to ACE2 expression on these vascular cells. In fact, a pathologic study showed direct evidence of viral invasion and resulting apoptosis in epithelial cells of various organs using electron microscopy. 43 

Heart failure and cardiogenic shock appear to be important causes of morbidity and mortality in COVID-19. In a study of 191 patients with confirmed COVID-19 from two Chinese hospitals, 23% (n=44) of patients had a clinical diagnosis of heart failure. 4 Of the patients who died during the study, 52% (n=28) had developed heart failure vs. 12% (n=16) with heart failure among survivors (p<0.0001). 4 In another retrospective case series of 150 patients with COVID-19 from two Chinese institutions, 33% (n=22) of deaths were attributed to respiratory failure with myocardial damage or heart failure with an additional 7% reported as heart failure without respiratory failure. 44 In a clinical review of these deaths, the researchers suggested that fulminant myocarditis may have been the etiology of the heart failure; however, no additional diagnostic details were included. Other potential causes of myocardial dysfunction have been discussed in an earlier section of this review. Some experts have speculated that the heart failure syndrome seen in COVID-19 is mediated predominantly through systemic inflammation and cytokine storm. 17 This theory is grounded in the reports from several studies that have shown markedly elevated inflammatory markers including IL-6, d-dimer and LDH in patients with severe COVID-19. At the time of this writing, only case reports have described the use of mechanical circulatory support devices in patients with cardiogenic shock as a complication of COVID-19. 30 Veno-venous extra-corporeal membrane oxygenation (V-V ECMO) is a treatment for refractory respiratory failure and veno-arterial ECMO may be used when the patient is also in need of circulatory support. 45 However, it is unknown whether particular populations of patients respond better to therapy with ECMO than others and what criteria are best used for careful selection of patients who are most likely to benefit in the present resource-constrained environment. Additionally, the time course for possible recovery and successful decannulation strategies from ECMO have not been well described at this time.

Diffuse thrombotic disease is an emerging concern in COVID-19. Other respiratory viral illnesses have been reported to predispose to patients to venous thromboembolism (VTE). 46 Also, in the prior experience with SARS, autopsies showed fibrin thrombi in 85% of cases with 71% of these associated with pulmonary infarction. 47 It is plausible that SARS-CoV-2 infection also increases VTE risk. A preliminary report identified microthrombi in the pulmonary vasculature in an autopsy of a patient who expired from COVID-19. 48 Another study showed that patients admitted with COVID-19 have high clinical risk scores for thromboembolic events. 49 An early report of thromboembolic events in COVID-19 from a case series of all patients with proven COVID-19 pneumonia that were admitted to any of three ICUs in the Netherlands found 31 thromboembolic events in this cohort (n=184), of which the majority were pulmonary embolism (n=25). 50 Of note, all of these patients were reportedly receiving pharmacological prophylaxis with low-molecular-weight heparin albeit there was underdosing relative to typical dosing at US hospitals in 2 of the 3 centers involved. 50 anti-viral therapies with liver function, some academic centers have developed guidelines that suggest to switch direct oral anticoagulants (DOACs) or warfarin to systemic heparin. 56 At least one trial of prophylactic antithrombotic therapy for patients with COVID-19 started in early April, 2020 (NCT04333407).

One case series reported the occurrence of arrhythmias of unspecified type in 17% of hospitalized patients with COVID-19 (n=23 of 138 total), with higher rate in ICU patients (44%, n=16) compared with non-ICU patients (7%, n=7). 3 Another case series of 187 hospitalized patients reported that sustained ventricular tachycardia or ventricular fibrillation occurred in 5.9% (n=11) of patients.

Influenza is also known to precipitate arrhythmias, particularly AV block and ventricular fibrillation. 57 The causal mechanism is unclear, but analogously to acute cardiac injury could be secondary to myocarditis, myocardial stress, or ischemia.

At the time of this writing, there are no pharmacotherapies specifically approved for the management of SARS-CoV-2 or the complications of COVID-19.

However, in addition to the supportive management described in the section that follows, clinical consideration has been given to off-label use of medications directed towards the virus itself ( 66 There are also case reports of using remdesivir in humans. 67 Two clinicals trials in China, one in patients with mild and moderate symptoms (NCT04252664) and one in patients with severe symptoms (NCT04257656), have been terminated due to lack of patient enrollment with improved control of the epidemic in that country. Several trials are still ongoing in the U.S. (NCT04292899, NCT04292730) . In a cohort of 61 hospitalized patients with oxygen saturation of 94% or less on ambient air who received remdesivir for compassionate use, 57% of patients receiving mechanical ventilation were successfully extubated, and 13% of the patients died. 68 The absence of a control group is a critical limitation of this preliminary study. While more comprehensive data on cardiac toxicities has yet to be published, there is a report of hypotension followed by cardiac arrest during a loading dose in a patient being treated for Ebola. 69 Elevation of hepatic transaminases have been reported in patients receiving remdesivir, raising concerns for hepatotoxicity in patients who are already critically ill. 70 Chloroquine has been used as an anti-malarial drug since the 1930s. Due to their immunomodulatory properties, chloroquine and it's hydroxyl-analogue hydroxychloroquine are also used to treat rheumatoid arthritis and systemic lupus erythematous. 56 These drugs have been shown to interfere with endosomemediated viral entry. 56, 72 They have also been shown to decrease proinflammatory cytokines, possibly decreasing the severity of cytokine storms.

Chloroquine has been shown to have in vitro antiviral activities against SARS-CoV-2. 63 An initial small, non-randomized, open-label French study, in which chloroquine and azithromycin appeared to have faster than expected viral clearance, has since been retracted due to methodological issues. 73 In a randomized trial of 62 patients in Shanghai, China, the treatment group (hydroxychloroquine 200 mg twice daily for between days 1-5) had shorter fever and cough duration. 74 Several larger randomized trials are ongoing in China and US that will provide more robust evidence on the efficacy of chloroquine and hydroxychloroquine. Of note, these medications can cause QT prolongation and potential risks for torsades de pointes especially when used concomitantly with other QT prolonging medications; careful monitoring is warranted. The ACC has suggested protocols for monitoring both in the clinical trials, inpatient and outpatient clinical care settings. 75 Hydroxychloroquine has also been associated with a higher risk of hypoglycemia in diabetes patients. 61 At the time of this writing, one of the randomized trials studying chloroquine (NCT04323527) was stopped early due to a concern for excess arrhythmias. 76

Lopinavir is a human immunosuppression virus (HIV)-1 protease inhibitor that is Table 1) .

Tocilizumab has been shown to increase fluid retention and potentially increase lipid profile, but was not found to increase risk of cardiovascular complications in large cohort studies. 84 Both medications can cause immunosuppression and increased risks of serious infections including tuberculosis, hypersensitivity, and increased liver enzymes. 85, 86 Sarilumab can also cause decreased neutrophil and platelet counts, and increased LDL and tryglycerides. 86

Convalescent serum from individuals who have recovered from viral infection has been used to treat patients with acute viral infections, such as Ebola, H5N1, and H1N1; although efficacy results were mixed. [87] [88] [89] [90] Convalescent serum was also used during the SARS pandemic and was found to be associated with higher 22day discharge rate (74% versus 19%, p<0.001). 91 In a more recent case series, needed. 92 Clinical trials are ongoing to test the feasibility and efficacy of using convalescent plasma ( Table 1) .

Cardiologists involved in the care of patients with COVID-19 face a wide range of care decisions in the context of a rapidly evolving but, as yet, modest evidence base (Figure 3) . In addition to experimental anti-viral and anti-inflammatory therapies discussed in the next section of this review, management is focused on supportive care aimed at mitigating the respiratory insufficiency that higher PEEP with the aim to mitigate the risk of high driving pressure (barotrauma) or tidal volumes (volutrauma), and oxygen-related toxicity. 95 COVID-19 is known to be a systemic illness with numerous complications other than cardiac. Abnormal liver enzymes are common but acute liver injury, defined as three times the upper limit of normal, appears to occur largely as a result of shock and critical illness. 20, 96 Acute kidney injury occurs at high rates for those hospitalized with severe manifestations of the disease. 4, 8, 20 Renal replacement therapy is needed in approximately 5% of patients with COVID-19 admitted to ICUs. 97 For critically ill patients, disseminated intravascular coagulation (DIC) has been noted but disturbances of coagulation in most patients with COVID-19 are characterized by a hypercoagulable profile with very high d-dimer and fibrinogen, possibly predisposing patients to macrovascular thrombosis. 50, 98 Standard guidelines for anticoagulation for prophylaxis of venous thromboembolism in acute medical illness should be followed assiduously and in some centers consideration is given to more intensive prophylactic anticoagulation. Lastly, potential drug-drug interactions between antiplatelet agents and anticoagulants with investigational COVID-19 therapies ought be considered when caring for patients requiring these cardiovascular therapies. 99 As yet, there are no evidence-based guidelines for monitoring of cardiovascular complications of COVID-19. Because of the observation that patients with COVID-19 with significantly elevated cardiac biomarkers (cardiac troponin, natriuretic peptides, CRP, d-dimer) tend to have worse outcomes, some centers are routinely measuring such biomarkers in a serial manner. 56 This approach is commensurate with the view that prognostic information in trending serial biomarkers may be useful for clinicians in better monitoring and predicting the disease course, helping to triage patients to appropriate level of care, and to inform the tailoring of vasoactive agents in shock. 100 In contrast, the ACC published a statement advising against routine testing of troponins and brain natriuretic peptide (BNP) in patients admitted with COVID-19, arguing that these tests should only be used when there is evidence of either myocardial infarction or new heart failure. 101 The routine use of cardiac imaging, including echocardiography, has been challenging for institutions trying to balance the risk for healthcare workers exposed to these patients versus the clinical utility of these tests; consequently, clinicians are being advised to use point-of-care ultrasound when possible. 102 Under normal circumstances, in a disease that is known to cause myocardial dysfunction and heart failure, a patient with high cardiac biomarkers and evidence of volume overload would likely prompt a transthoracic echocardiogram; however, in the setting of COVID-19 careful consideration should be given to whether the imaging study will affect management and whether or not a point-of-care ultrasound is applicable as a screening tool. If acute cardiac diseases or complications are identified, treatment for heart failure, cardiogenic shock, and myocarditis should generally follow clinical practice guidelines irrespective of COVID-19, including the use of inotropes and mechanical circulatory support, when appropriate in the context of the patient's overall prognosis and availability of resources. 94 Invasive evaluation for suspected ongoing myocardial ischemia has been discussed in an earlier section of this review.

COVID-19 is more than a respiratory illness; it is now understood to have broad systemic effects, including cardiovascular manifestations. (Figure 1 ) Cardiac injury may occur through possible ischemic and non-ischemic mechanisms. J o u r n a l P r e -p r o o f 

The Johns Hopkins Coronavirus Resource Center. Coronavirus

Global Cases by the Center for Systems Science and Engineering

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Coronavirus Infections-More Than Just the Common Cold

In the Absence of SARS-CoV Transmission Worldwide: Guidance for Surveillance, Clinical and Laboratory Evaluation, and Reporting

COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

Centers for Disease Control and Prevention. How Coronavirus Spreads. 2020

Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient

Evidence for gastrointestinal infection of SARS-CoV-2

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 2020. 15

Public Health Responses to COVID-19 Outbreaks on Cruise Ships -Worldwide

COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal

Chinese Center for Disease Control and Prevention. Tracking the Epidemic -National Health Commission Update

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical Characteristics of Coronavirus Disease 2019 in China

Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

Addresses Concerns Re: Using RAAS Antagonists in COVID-19

European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Troponin elevation in coronary vs. non-coronary disease

Considerations for Cardiac Catheterization Laboratory Procedures During the COVID-19 Pandemic Perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates

The Variety of Cardiovascular Presentations of COVID-19

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

Seasonal Influenza Infections and Cardiovascular Disease Mortality

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Elevated cardiac troponin measurements in critically ill patients

Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum

Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock

Dysregulation of intracellular calcium transporters in animal models of sepsis-induced cardiomyopathy

First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights

COVID-19 and the cardiovascular system

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Endothelial cell infectionand endotheliitis in COVID-19

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure

Review: Viral infections and mechanisms of thrombosis and bleeding

Pulmonary pathology of severe acute respiratory syndrome in Toronto

Clinical pathology of critical patient with novel coronavirus pneumonia ( COVID-19)

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

A major outbreak of severe acute respiratory syndrome in Hong Kong

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury

American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy

Brigham and Women's Hospital. Brigham and Women's Hospital COVID-19

The cardiovascular manifestations of influenza: a systematic review

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

First Case of 2019 Novel Coronavirus in the United States

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Controlled Trial of Ebola Virus Disease Therapeutics

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet Infectious Diseases

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Human immunopathogenesis of severe acute respiratory syndrome (SARS)

Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study

Highlights of Prescribing Information -Tocilizumab Package Insert

Highlights of Prescribing Information -Sarilumab Package Insert

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease

Treatment with convalescent plasma for influenza A (H5N1) infection

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Use of convalescent plasma therapy in SARS patients in Hong Kong

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

Disruptive Modifications to Cardiac Critical Care Delivery During the Covid-19 Pandemic: An International Perspective

Management of Critically Ill Adults With COVID-19

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction

ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak